Events & Presentations
Date | Event Details | Remind Me |
---|---|---|
Apr 3 - Apr 4, 2023
|
7th Complement UK Training Course and Symposium
|
Date | Event Details |
---|---|
Feb 2, 2022 4:30 PM EST
|
Arrowhead Pharmaceuticals 2022 First Quarter Results
Prepared Remarks 206.2 KB
|
Dec 3, 2021
|
18th Global Cardiovascular Clinical Trialists Forum
View Presentation 1.1 MB
James Hamilton, MD, MBA, Arrowhead’s senior vice president of discovery & translational medicine, will participate in a panel discussion titled, “Developments in Hypertriglyceridemia Trials”
|
Dec 2, 2021 1:00 PM EST
|
4th Annual Evercore ISI HealthCONx Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
|
Nov 30, 2021
|
Piper Sandler 33rd Annual Healthcare Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
|
Nov 22, 2021 4:30 PM EST
|
Arrowhead Pharmaceuticals 2021 Year End Results
Prepared Remarks 210.1 KB
|
Nov 16, 2021 11:50 AM EST
|
Jefferies London Healthcare Conference
Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
|
Nov 13 - Nov 17, 2021
|
American Heart Association (AHA) Scientific Sessions 2021
Title: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia |
Nov 12 - Nov 15, 2021
|
The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
AASLD 2021 AROAAT2002 poster 1.3 MB
AASLD 2021 AROHSD1001 poster 1.5 MB
AASLD 2021 REEF-1 Late-Breaker Oral 484.5 KB
Title: ARO-AAT Treatment Reduces Intra-hepatic Z-AAT Leading to Improved Parameters of Liver Health and Fibrosis Regression Title: ARO-HSD, An Investigational RNAi Therapeutic, Demonstrates Reduction in ALT and Hepatic HSD17B13 mRNA and Protein in Patients with NASH or Suspected NASH Title: Efficacy and Safety of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator (CAM) JNJ-6379 for the Treatment of Chronic Hepatitis B Virus Infection (CHB): Results from the Phase 2B REEF-1 Study |
Oct 26, 2021 3:00 PM EDT
|
ARO-C3 KOL Webinar
View Presentation 3.8 MB
|
Oct 12, 2021 2:00 PM EDT
|
H.C. Wainwright 5th Annual NASH Investor Conference
James Hamilton, M.D., MBA, Arrowhead’s senior vice president of discovery and translational medicine will participate in a fireside chat presentation
|